Advanced search
Publication Cover
Annals of Medicine Volume 55, 2023 - Issue 1
Submit an article Journal homepage
1,490
Views
2
CrossRef citations to date
0
Altmetric
Pulmonary Medicine

The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study

Qing Songa Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Ling Lina Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Aiyuan Zhoud Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Wei Chenga Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaORCID Iconhttps://orcid.org/0000-0003-1025-0591View further author information
ORCID Icon,
Cong Liua Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Yating Penga Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaORCID Iconhttps://orcid.org/0000-0003-2345-4059View further author information
ORCID Icon,
Zijing Zhoua Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Yuqin Zenga Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Dingding Denge Department of Respiratory Medicine, The First Attached Hospital of Shaoyang University, Shaoyang, Hunan, ChinaView further author information
,
Dan Liuf Department of Respiratory, The Eighth Hospital in Changsha, Hunan, ChinaView further author information
,
Zhiping Yug Department of Respiratory, Longshan Hospital of Traditional Chinese Medicine, Hunan, ChinaView further author information
,
Yan Chena Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
,
Shan Caia Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaView further author information
&
Ping Chena Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;b Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China;c Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1317-1324 | Received 02 Nov 2022, Accepted 13 Mar 2023, Published online: 29 Mar 2023

References

  • GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596.
  • Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
  • GOLD Executive Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 REPORT). 2018 [cited 2018 November 4]. Available from: https://goldcopd.org/
  • Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
  • Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.
  • Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935.
  • Song Q, Zhao YY, Zeng YQ, et al. The characteristics of airflow limitation and future exacerbations in different GOLD groups of COPD patients. Int J Chron Obstruct Pulmon Dis. 2021;16:1401–1412.
  • Cui Y, Dai Z, Luo L, et al. Classification and treatment of chronic obstructive pulmonary disease outpatients in China according to the global initiative for chronic obstructive lung disease (GOLD) 2017: comparison with GOLD 2014. J Thorac Dis. 2019;11(4):1303–1315.
  • Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD network registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955.
  • Zhao YY, Liu C, Zeng YQ, et al. Modified and simplified clinically important deterioration: multidimensional indices of short-term disease trajectory to predict future exacerbations in patients with chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620977376.
  • Ninane V, Corhay JL, Germonpré P, et al. Inhaled treatment of COPD: a Delphi consensus statement. Int J Chron Obstruct Pulmon Dis. 2017;12:793–801.
  • Zeng Y, Cai S, Chen Y, et al. Current status of the treatment of COPD in China: a multicenter prospective observational study. Int J Chron Obstruct Pulmon Dis. 2020;15:3227–3237.
  • Price D, Miravitlles M, Pavord I, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med. 2016;26:16061.
  • Larsson K, Ekberg-Jansson A, Stridsman C, et al. Adherence to treatment recommendations for chronic obstructive pulmonary disease – results from the Swedish national airway register. Int J Chron Obstruct Pulmon Dis. 2021;16:909–918.
  • Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922.
  • Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.
  • Lee SJ, Yun SS, Ju S, et al. Validity of the GOLD 2017 classification in the prediction of mortality and respiratory hospitalization in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:911–919.
  • Cheng W, Duan J, Zhou A, et al. Real-World effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study. Front Pharmacol. 2021;12:53653.
  • Pelaia C, Procopio G, Deodato MR, et al. Real-Life clinical and functional effects of fluticasone furoate/umeclidinium/vilanterol-combined triple therapy in patients with chronic obstructive pulmonary disease. Respiration. 2021;100(2):127–134.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.